Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Novozymes is a world leader in bioinnovation. Novozymes works with its partners to innovate new solutions and rethink industries around the world. Novozymes' industrial enzymes, microorganisms, biopolymers, and other proteins allow its customers to achieve more efficient use of raw materials, reduce energy consumption, replace traditional chemicals with more sustainable alternatives, and offer higher-quality products. Novozymes rethinks everyday products every day.

Novozymes Biopharma DK A/S engages in the wholesale of pharmaceuticals and medical article. The firm operates and invests in research, development, production, and trade in biological solutions, including pharmaceuticals, and biotechnology products and processes.The company was founded on May 29, 2006 and is headquartered in Bagsvaerd, Denmark.

Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

Unitika Ltd. engages in the polymer and functional materials business. It operates through the following business segments: Polymer, Functional Material, Fiber, and Others. The Polymer segment manufactures and sells plastic film, resin, and non-woven cloth. The Functional Material segment handles the manufacture and sale of glass fibers. The Fiber segment deals with the manufacture and sale of various fibers such as thread, cotton, and knitted fibers. The Others segment includes environmental business, medical business, lifestyle and wellness, and real estate businesses. The company was founded on June 19, 1889 and is headquartered in Osaka, Japan.

Amano Enzyme, Inc. manufactures and distributes enzymes for pharmaceuticals, food and diagnostics. It also produces and sells feed additives, drugs, and animal drugs. The company was founded in 1899 by Ennosuke Amano and is headquartered in Nagoya, Japan.

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

CJ CheilJedang is a core subsidiary in charge of the food and bioengineering business Unit of the CJ Group. It has led the development of the Korean food industry for the past 60 years, and contributed to the development of the bioengineering industry as the nation’s top food originated company. After being launched in 1953 as a food ingredient company, continuously extended its business to processed foods. In 2007, CJ CheilJedang divided out as a subsidiary company to concentrate on the food and bioengineering business.

Shanghai Yijue Biotechnology Co., Ltd., established on 2007-04-05, The scope of business includes engaging in technology development in the field of biological science and technology,technology transfer,technical consulting,Technical Services,Sales of Class II Medical Devices. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Yuki Gosei Kogyo Co. Ltd. engages in the manufacture and sale of medical products. It operates through the following divisions: Amino Acids, Chemical Products, Pharmaceuticals, Manufacturing Contract, and Sales-related Contract. The Amino Acids division manufactures and sells amino acids and vitamins. The Chemical Products division manufactures and sells raw tire cord adhesive materials, agricultural chemicals intermediates, and silicon compound. The Pharmaceuticals division produces and markets raw materials and intermediates for pharmaceutical products. The Manufacturing Contact division handles contract manufacturing operations. The Sales-related Contract division handles contract for sales-related business. The company was founded on November 4, 1947 and is headquartered in Tokyo, Japan.

Shanghai Beijia Biochemical Reagent Co., Ltd., established on 2002-01-11, The scope of business includes Class II6840Production of in vitro diagnostic reagents,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

The National Institute of Advanced Industrial Science and Technology (AIST), led by President Chubachi, is a public research institution funded by the Japanese government to a large extent. The present AIST is a rather new research organization established in 2001. However, AIST and its predecessor organizations have been contributing to society through continuous advancement in technologies and support to Japanese industries since 1882. Headquarters of AIST are located in Tsukuba and Tokyo. AIST has over 40 autonomous research units in various innovative research fields, and the units are located at ten research bases and several sites (smaller than research bases) of AIST all over Japan. About 2300 researchers (about 2000 with tenure: about 80 from abroad) and a few thousands of visiting scientists, post-doctoral fellows, and students from home and abroad are working at AIST. About 650 permanent administrative personnel and many temporary staff support research works of AIST.

Degussa-Hüls AG manufactures and supplies chemical products. It produces industrial chemicals, creavis, iron metal producer, specialty polymers, advanced fillers, performance materials, specialty chemistry, iron and hardening. The company was founded in 1999 and is located in Hanau, Germany.

Shenzhen Lijian Brain Science Technology Co., Ltd., established on 2015-08-05, Business scope includes general business items:Applied Optical Equipment,Optical engineering equipment,Precision Machinery and Instruments,Electronic appliances,,Communication Products,Electronic industry special equipment,Research and development of mechanical and electrical equipment and accessories,design,Sales,Home maintenance;Technology development in the field of optical technology,technology transfer,Technical Consulting and Technical Services;computer software development;Operating import and export business;Domestic Trade;Development of Cognitive Brainwave Detector,Sales,Rental and door-to-door service;R&D and sales of new energy batteries(above according to the law,Administrative regulations,Decisions of the State Council and other regulations that require approval,Can only operate after obtaining relevant approval documents according to law).,The licensing program is:Applied Optical Equipment,Optical engineering equipment,Precision Machinery and Instruments,Electronic appliances,Communication Products,Electronic industry special equipment,Electromechanical equipment and accessories,Production of Cognitive Brainwave Detector.

Mitsui Chemicals, Inc. manufactures and sells petrochemicals and industrial inorganic chemical products. It operates through the following segments: Mobility, Healthcare, Food and Packaging, Base Material, and Others. The Mobility segment covers the new product development support business (solution business) for elastomers, functional compounds, functional polymers, polypropylene compounds, automobiles and other industrial products. The Healthcare segment includes vision care material, non-woven fabric, dental material, and personal care material. The Food and Packaging segment handles the coating and functional materials, functional films and sheets, and agricultural chemicals. The Base Material segment covers the ethylene, propylene, polyethylene, polypropylene, catalysts, phenols, high-purity terephthalic acid, PET resins, polyurethane materials, and industrial chemicals. The Others segment comprises of other related businesses. The company was founded on July 1, 1955 and is headquartered in Tokyo, Japan.